

Olaparib OlympiAD

PRELIMINARY SCORE

CURATIVE




NON-CURATIVE




ADJUSTMENTS

Quality of life



Delayed deterioration in global QoL

Serious and disabling adverse effects



Less serious and disabling adverse events observed

Other adjustments



Olaparib OlympiAD

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Treatment of patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or MBC who have been previously treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless unsuitable for these treatments
 Experimental Arm: Olaparib
 Control Arm: Standard chemotherapy



